General
Preferred name
TERIFLUNOMIDE
Synonyms
A 77-1726 ()
A77 1726 ()
HMR-1726 ()
Flucyamide ()
Aubagio ()
(E/Z)-Teriflunomide ()
2-cyano-3-hydroxy-n-[4-(Trifluoromethyl)phenyl]but-2-enamide ()
(E/Z)-A77 1726 ()
A77 1726, HMR-1726 ()
Leflunomide related compound b ()
HMR1726 ()
Leflunomide related compound b rs ()
A-771726 ()
P&D ID
PD010419
CAS
108605-62-5
163451-81-8
Tags
available
drug
Approved by
EMA
FDA
First approval
2012
Drug Status
approved
Drug indication
Hepatitis B virus infection
Rheumatoid arthritis
Hyperlipidaemia
Multiple sclerosis
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Teriflunomide inhibits dihydroorotate dehydrogenase (DHODH). It is the active metabolite of . (GtoPdb)
MOA The exact mechanism by which teriflunomide acts in MS is not known. What is known is that teriflunomide prevents pyrimidine synthesis by inhibiting the mitochondrial enzyme; dihydroorotate dehydrogenase, and this may be involved in its immunomodulatory effect in MS.
PHARMACODYNAMICS Teriflunomide is an immunomodulatory agent that decreases the amount of activated CNS lymphocytes, which results in anti-inflammatory and antiproliferative effects.;
ROE Teriflunomide is eliminated unchanged and mainly through bile. Specifically 37.5% is eliminated in the feces and 22.6% in urine.;
ABSORPTION After oral administration of teriflunomide, maximum plasma concentrations are reached, on average, in 1-4 hours.; ;
DESCRIPTION Inhibits dihydroorotate dehydrogenase
DESCRIPTION Dihydroorotate dehydrogenase inhibitor (Tocriscreen Plus)
DESCRIPTION Adenylyl cyclase inhibitor (Tocris Bioactive Compound Library)
Cell lines
3
Organisms
1
Compound Sets
26
Cayman Chemical Bioactives
14404
ChEMBL Approved Drugs
CHEMBL973
ChEMBL Drugs
CHEMBL973
Concise Guide to Pharmacology 2017/18
6844
Concise Guide to Pharmacology 2019/20
6844
Concise Guide to Pharmacology 2021/22
6844
Concise Guide to Pharmacology 2023/24
6844
DrugBank
DB08880
DrugBank Approved Drugs
DB08880
DrugCentral
4634
DrugCentral Approved Drugs
4634
DrugMAP
DMQ2FKJ
DrugMAP Approved Drugs
DMQ2FKJ
EU-OPENSCREEN Bioactive Compound Library
EOS100620
Guide to Pharmacology
6844
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL973
Mcule NIBR MoA Box Subset
MCULE-7183335350
MedChem Express Bioactive Compound Library
HY-110159
HY-15405
NCATS Inxight Approved Drugs
1C058IKG3B
Novartis Chemogenetic Library (NIBR MoA Box)
Other bioactive compounds
ReFrame library
Selleckchem Bioactive Compound Library
teriflunomide
TargetMol Bioactive Compound Library
T3044
Tocris Bioactive Compound Library
5069
Tocriscreen Plus
5069
External IDs
40
Properties
(calculated by RDKit )
Molecular Weight
270.06
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
2
Rotatable Bonds
2
Ring Count
1
Aromatic Ring Count
1
cLogP
3.0
TPSA
73.12
Fraction CSP3
0.17
Chiral centers
0.0
Largest ring
6.0
QED
0.49
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
Enzymes
Pathway
Metabolism
Metabolic Enzyme/Protease
Target
Dihydroorotate Dehydrogenase
Drug Metabolite
Dehydrogenase,Immunology & Inflammation related
MOA
Inhibitor
Dihydroorotate Dehydrogenase (DHODH) Inhibitors
Member status
member
Source data